FDA approvals are critical milestones for biotech companies, often leading to significant stock price appreciation. The approval of CASGEVY confirms CRISPR Therapeutics' capability to bring innovative treatments to market, which can enhance its reputation and lead to increased sales and revenue. This news is highly relevant and important to the company's prospects, and there is high confidence that the stock will react positively in the short term.